Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 1223Neoplasms 1041Carcinoma, Non-Small-Cell Lung 755Prostatic Neoplasms 693Colorectal Neoplasms 593Lung Neoplasms 574Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 399Neoplasm Metastasis 387Multiple Myeloma 374Ovarian Neoplasms 372Stomach Neoplasms 317Carcinoma, Hepatocellular 303Melanoma 282Recurrence 281Brain Neoplasms 281Squamous Cell Carcinoma of Head and Neck 268Head and Neck Neoplasms 237Endometrial Neoplasms 235Glioblastoma 234Triple Negative Breast Neoplasms 230Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Uterine Cervical Neoplasms 225Lymphoma 224Hematologic Neoplasms 200Sarcoma 199Urinary Bladder Neoplasms 197Esophageal Neoplasms 191Carcinoma, Renal Cell 190Lymphoma, Non-Hodgkin 176

Interventions

olaparib 1decitabine and cedazuridine drug combination 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × BRCA1 Mutation × 1 year × Clear all
NCT06177171 2026-05-27

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

University of California, San Francisco

Phase 1 Recruiting
18 enrolled

BRCA1 Mutation

NCT05420064 2025-11-12

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results

Memorial Sloan Kettering Cancer Center

Phase NA Recruiting
1,000 enrolled

BRCA1 Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡